Item 1.01 Entry into a Material Definitive Agreement.

On July 12, 2022, Greenwich LifeSciences, Inc. (the "Company") entered into an Open Market Sale Agreement (the "Sale Agreement") with Jefferies LLC ("Jefferies"), as sales agent. Pursuant to the terms of the Sale Agreement, the Company may issue and sell from time to time shares of its common stock, par value $0.001 per share, through Jefferies, acting as its sales agent. Pursuant to the Company's prospectus supplement filed on July 12, 2022, the Company may issue and sell shares of its common stock having an aggregate offering price of up to $100.0 million (the "Shares").

Under the Sale Agreement, Shares will be offered and sold pursuant to the Company's shelf registration statement on Form S-3 (File No. 333-263855) filed with the Securities and Exchange Commission (the "SEC") on March 25, 2022, declared effective by the SEC on April 6, 2022. In addition, under the Sale Agreement, sales of Shares may be made by any method permitted by law deemed to be an "at the market offering" as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended.

The Company will pay Jefferies a commission rate of up to 3.0% of the gross proceeds from each sale of Shares and has agreed to provide Jefferies with customary indemnification and contribution rights. The Company will also reimburse Jefferies for certain specified expenses in connection with entering into the Sale Agreement.

The Company has no obligation to sell any of the Shares under the Sale Agreement and may at any time suspend the offering of its common stock upon notice and subject to other conditions.

The Sale Agreement contains customary representations, warranties and agreements by the Company, other obligations of the parties and termination provisions.

The Company intends to use the net proceeds from the sale of any Shares sold under the Sale Agreement for general corporate purposes, which may include, among other things, funding the clinical development and manufacturing and expenses for GP2, research and development, general and administrative expenses, license or technology acquisitions, and working capital and capital expenditures.

A copy of the Sale Agreement is filed as Exhibit 1.1 to this Current Report on Form 8-K, and the description of the terms of the Sale Agreement in this Item 1.01 is qualified in its entirety by reference to such exhibit. A copy of the opinion of Sheppard Mullin Richter & Hampton LLP relating to the legality of the issuance and sale of the Shares is attached as Exhibit 5.1 hereto.

This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy any Shares, nor shall there be any sale of Shares in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits.



1.1      Open Market Sale Agreement, dated July 12, 2022 by and between the
       Company and Jefferies LLC.
5.1      Opinion of Sheppard Mullin Richter & Hampton, LLP
22.1     Consent of Sheppard Mullin Richter & Hampton, LLP (included in Exhibit
       5.1)
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)



-2-

© Edgar Online, source Glimpses